EMEA-001637-PIP01-13

Key facts

Active substance
Human normal immunoglobulin
Therapeutic area
Immunology-Rheumatology-Transplantation
Decision number
P/0047/2014
PIP number
EMEA-001637-PIP01-13
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Treatment of Primary Immunodeficiency (PID)
Route(s) of administration
Subcutaneous use
Contact for public enquiries
Baxter Innovations GmbH
Ausria
E-mail: europa_biosci_globalra@baxter.com
Tel. +43 1201000
Fax +43 120100 / 2475990
Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Compliance procedure number
EMEA-001637-PIP01-13
Compliance opinion date
16/01/2015
Compliance outcome
positive

Decision

How useful was this page?

Add your rating